WO2019155266A1 - Flavocillin: a new novel antibitoic that the bacteria will never develop - Google Patents
Flavocillin: a new novel antibitoic that the bacteria will never develop Download PDFInfo
- Publication number
- WO2019155266A1 WO2019155266A1 PCT/IB2018/050851 IB2018050851W WO2019155266A1 WO 2019155266 A1 WO2019155266 A1 WO 2019155266A1 IB 2018050851 W IB2018050851 W IB 2018050851W WO 2019155266 A1 WO2019155266 A1 WO 2019155266A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flavocilin
- flavonoid
- methods
- antibiotic
- penicilin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6
- C07D499/74—Compounds with an amino radical acylated by carboxylic acids, attached in position 6 with carbocyclic rings directly attached to the carboxamido radical
Definitions
- Flavocillin A new novel antibitoic that the bacteria will never develop resistance
- Flavocilin For obtaining Flavocilin, the R group must be replaced with a basic flavonoid and there may be more ways than what is being described at the claims part of this invention. Fortunately, obtaining Flavocilin is a simple Chemical process as a conclusion drawn from its theoretical studies.
- Flavonoids are very useful antimicrobial compounds of herbal origin found naturally in certain teas and Propolis, a solution available to be used in Medicine which is what the honey bee uses to prevent his honey comb from microbes while producing honey.
- Propolis alone readily available from Holland and Barret Stores, is full of flavonoids and as such it is effective in treating certain respiratory tract infections and also persistent flue, as a natural remedy.
- Flavocilin can easily be obtained with simple reactions.
- Flavocilin can always be used as a final choice of antibiotic where patient responds to no other antibiotic treatment, and it is impossible not to respond to Flavocilin due to dual mechanism of action stated previously.
- Flavocilin will be the solution for the problem of the century, antibiotic resistance, even after centuries due to penicilin-flavonoid dual strength effects.
- Flavocilin needs to be tested against virus effectiveness also. Due to its flavonoid group and Penicilin group, it can have a wider range of Pharmacological use and tests can determine if it will cancel, prevent, treat or minimise viral resistance, and if so, to what levels? The likelihood of finding out that it is very powerful against virus also will add benefit to its revolutionary importance and non-competitive unique advantages.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
This invention is about the discovery of a new novel compound as an antibiotic to stop this potential resistance problem completely. With Organic Chemistry studies and methods and other modified antibiotics, adding a flavonoid group to varibale side R instead which will result in flavocilin formation will be the most effective and revolutionary antibiotic that the bacteria will never be able to resist. Evidentful pathways have been conculded stating that the Flavocilin use in Medicine for heavy infectious conditions or where no other antibiotic works will outweigh all its risks.
Description
Flavocillin: A new novel antibitoic that the bacteria will never develop resistance
Resistance to antibiotics is a complicated growing problem of the centruy. Presently, this problem has been so much getting the attention of Medical Research Institutions and health organizations that there is a huge alert in preventing antibiotic resistance. There are reports estimating that many people will die in 2050’s due to antibiotics not working anymore as a result of this resistance. The simplest evidence that Flavocillin will be an effective antibiotic is that many stronger antibiotics were obtained by modifying the variable group (R) in Penicilin Chemical structure.
For obtaining Flavocilin, the R group must be replaced with a basic flavonoid and there may be more ways than what is being described at the claims part of this invention. Fortunately, obtaining Flavocilin is a simple Chemical process as a conclusion drawn from its theoretical studies.
Flavonoids are very useful antimicrobial compounds of herbal origin found naturally in certain teas and Propolis, a solution available to be used in Medicine which is what the honey bee uses to prevent his honey comb from microbes while producing honey. Propolis alone, readily available from Holland and Barret Stores, is full of flavonoids and as such it is effective in treating certain respiratory tract infections and also persistent flue, as a natural remedy.
In drug discovery and development process, adding effective Bioactive compounds to R groups of already active Chemical compounds as drug molecules is important to obtain much stronger effects than that of those drug molecules being used alone in treatment.
Possible advantages and disadvantages of Flavocilin as a new drug
development
Advantages:
Due to dual destructive mechanism effects (Cell wall inhibition and microbial destruction by bioactive flavonoid group as R (variable) group of Penicillin), the bacteria will never have the ability to resist to Flavocilin and therefore it will be the most powerful antibiotic via this defined dual strength of bioactivity.
As suggested in Chemical synthesis route part of claims, Flavocilin can easily be obtained with simple reactions.
Non-competitive advantage for the developer industry or for the drug company as a company holding the license rights of production during 20 years of patent protection.
Flavocilin can always be used as a final choice of antibiotic where patient responds to no other antibiotic treatment, and it is impossible not to respond to Flavocilin due to dual mechanism of action stated previously.
Flavocilin will be the solution for the problem of the century, antibiotic resistance, even after centuries due to penicilin-flavonoid dual strength effects.
Flavocilin needs to be tested against virus effectiveness also. Due to its flavonoid group and Penicilin group, it can have a wider range of Pharmacological use and tests can determine if it will cancel, prevent, treat or minimise viral resistance, and if so, to what levels? The likelihood of finding out that it is very powerful against virus also will add benefit to its revolutionary importance and non-competitive unique advantages.
Disadvantages:
Stronger effects may bring further side effects (but as flavonids are naturally found in tea and little or moderate tea consumption is known to have no noticable toxic effects, this risk is not likely).
Clinical testing to fully determine Pharmacological effects have not yet been determined.
Easy making of flavocilin can result in easy illegal flavocilin production (This is a probability but yet it is not very likely as per strict regulationbs and restrictions of patent law and also because a laboratory is still needed for its production although the method is not quite complicated.
References:
1. Nature volume 179, pages 892-893 (04 May 1957) doi: 10.1038/179892a0
2. J. Am. Chem. Soc. , 1957, 79 (5), pp 1262-1263. DOI:
10.1021/ja01562a063
3. Protein Sci. 2009 Mar; 18(3): 595-605. doi: 10.1002/pro.67 PMCID:
PMC2760365
Claims
1. This invention is about the discovery of a new novel antibiotic of maximum effectiveness that can ever be obtained by simpler than usual Chemical synthesis and modification methods, namely“Flavocilin”.
2. Flavocilin will overcome all the possible and potential antibiotic resistance problems and mechanisms as per stated mechnaisms of action and its unqiue and basic structure will be the strongest antibiotic ever used in Medicine, according to claim 1.
3. Flavocilin will consist of a flavonoid as R group attached to basic penicilin structure, according to claim 2.
4. Flavocilin can simply be obtained/synthesized in a Chemistry laboratory as following moderate detail synthesis methods (Other synthetic methods can also be developed besides this and grams and scales yet need to be determined by expert Organic/synthetic Chemists in field): Any basic flavonoid or a flavone solution is firstly extracted from a herbal tea by using any one of dichloromethane, diethyl ether, chloroform or ethyl acetate as a solvent. There are more than one way of extraction and many of these methods are available from many different public resources. The flavonoid extract is then isolated from the rest of the tea and H2S04 is added to the isolated flavonoid solution to produce lone paired Oxygens (as Flavonoids contain Oxygen around Cyclic carbons). The solution is then reacted with a readily available penicilin powder so that the formed lone pairs around Oxygen(s) in flavonoid attack the carbon attached to NH, O and R groups of Penicilin. This will result in double bond brokage and newly formed bond with the flavonoid due to an SN reaction. Since Penicilin contains Sulphur atom and methyls, an acid or other acidic compounds such as Sulphuric acid is likely to be resulted from this reaction, but such formed acids can easily be removed with the addition of a base to the solution resulting in salt formation that can be extracted and isolated later on so that it is gotten rid as it is unwanted. Finally, identification methods such as High Performance Liquid Chromatography (HPLC) and Carbon NMR must be used to analyze the solution to ensure the finally obtained sample contains Flavocilin and to ensure its structure represents the Flavocilin structure as identified in figure 2 of drwaings part of the invention. Once this is ensured, the very final step of the process is to purify the sample with
purification methods to obtain 99% Flavocilin. Alternative synthetic routes or pathways at any stage is also possible.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/050851 WO2019155266A1 (en) | 2018-02-12 | 2018-02-12 | Flavocillin: a new novel antibitoic that the bacteria will never develop |
EP18713342.6A EP3752509A1 (en) | 2018-02-12 | 2018-02-12 | Flavocillin: a new penicillin derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/050851 WO2019155266A1 (en) | 2018-02-12 | 2018-02-12 | Flavocillin: a new novel antibitoic that the bacteria will never develop |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019155266A1 true WO2019155266A1 (en) | 2019-08-15 |
WO2019155266A8 WO2019155266A8 (en) | 2020-06-18 |
Family
ID=61768349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/050851 WO2019155266A1 (en) | 2018-02-12 | 2018-02-12 | Flavocillin: a new novel antibitoic that the bacteria will never develop |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3752509A1 (en) |
WO (1) | WO2019155266A1 (en) |
-
2018
- 2018-02-12 EP EP18713342.6A patent/EP3752509A1/en active Pending
- 2018-02-12 WO PCT/IB2018/050851 patent/WO2019155266A1/en unknown
Non-Patent Citations (4)
Title |
---|
ANA CRISTINA ABREU ET AL: "Combinatorial Activity of Flavonoids with Antibiotics Against Drug-Resistant Staphylococcus aureus", MICROBIAL DRUG RESISTANCE., vol. 21, no. 6, 1 December 2015 (2015-12-01), US, pages 600 - 609, XP055474797, ISSN: 1076-6294, DOI: 10.1089/mdr.2014.0252 * |
J. AM. CHEM. SOC., vol. 79, no. 5, 1957, pages 1262 - 1263 |
NATURE, vol. 179, 4 May 1957 (1957-05-04), pages 892 - 893 |
PROTEIN SCI., vol. 18, no. 3, March 2009 (2009-03-01), pages 595 - 605 |
Also Published As
Publication number | Publication date |
---|---|
EP3752509A1 (en) | 2020-12-23 |
WO2019155266A8 (en) | 2020-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ebiloma et al. | Bioassay-guided isolation of active principles from Nigerian medicinal plants identifies new trypanocides with low toxicity and no cross-resistance to diamidines and arsenicals | |
CN105503531A (en) | Extract of fungus culture as well as preparation method and application of extract | |
WO2019155266A1 (en) | Flavocillin: a new novel antibitoic that the bacteria will never develop | |
CN102276632A (en) | Praziquantel derivative as well as preparation and application thereof | |
Parmar et al. | Mast cell membrane stabilization and anti-histaminic actions possible mechanism of action of anti-inflammatory action of Murraya koenigii | |
RU2572231C1 (en) | Method for producing antibacterial preparation of manna gum leaves | |
CN107212029A (en) | Herba Agrimoniae extract is being prepared for removing the application in tomato plant in the medicine of plant virus | |
RU2519666C1 (en) | Agent showing anti-opisthorchiasis action, and method for preparing it | |
CN101385796B (en) | New use of a formulation in improving cognition dysfunction and preventing and treating senile dementia | |
CN109496211B (en) | Piperazine derivative for resisting candida albicans as well as preparation method and application thereof | |
RU2615356C1 (en) | Method for lutenurinum preparation manufacture from yellow water-lily (nuphar lutea (l) smith) | |
Marks | Sea Lavender Endophyte's | |
Okere et al. | Antibacterial and antifungal activity of methanolic leaf extract of Allium sativum on selected pathogenic strains | |
Banerjee et al. | A STUDY TO EVALUATE THERAPEUTIC POTENTIAL OF POGOSTEMON CABLIN OIL AGAINST EXPERIMENTALLY INDUCED ALZHEIMER’S DISEASE IN MICE | |
Devi et al. | Organic solvents can influence acetylcholine neurotransmission in Caenorhabditis elegans | |
RU2664453C1 (en) | Derivative of 3-hydroxypyridine with anxiolytic and nootropic effect | |
Innocent et al. | SYSTEMATIC ANALYSIS OF ANTIBACTERIAL ACTIVITY OF PLANT EXTRACTS FROM PHYTOLACCA DODECANDRA AND DATURA STRAMONIUM | |
Ganaie | Fungal Diseases of Animals: Symptoms and Their Cure by Natural Products | |
WO2023237795A1 (en) | Use of the (+)-elatol compound for treating or preventing a naegleria fowleri infection | |
CN102091105B (en) | New application of field pennycress and preparation thereof | |
Aleksandrova et al. | Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases | |
Agbafor et al. | Catalase and superoxide dismutase (SOD) activity in albino rats treated with aqueous leaf extract of ageratum conyzoides | |
Mogaka et al. | Evaluation of the Therapeutic Potential of Warburgia ugandensis, Prunus africana, and Piliostigma thonningii against Leishmania donovani in vitro and in Balb/c Mice | |
BR102019014583A2 (en) | methodology of the process of biosynthesis of secondary metabolites of endophytic fungi with inhibitory activity against caseous lymphadenitis | |
Kang et al. | A study of the biodiversity and secondary metabolites of fungal endophytes from medicinal plants in Guizhou |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18713342 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018713342 Country of ref document: EP Effective date: 20200914 |